PATIENT-REPORTED OUTCOMES AND ECONOMIC BURDEN BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN JAPAN: ANALYSIS FROM THE JAPAN NATIONAL HEALTH AND WELLNESS SURVEY
Author(s)
Satoru Tanaka, MSc1, Soohyun Hwang, PhD, MPH2, Adam Jauregui, MSc2, Nikoletta Sternbach, BA2, Nobuhiro Osada, PhD1, Yoshio Kobayashi, MD, PhD, FJCC3.
1Amgen K.K., Tokyo, Japan, 2Oracle Life Science, Austin, TX, USA, 3Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
1Amgen K.K., Tokyo, Japan, 2Oracle Life Science, Austin, TX, USA, 3Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
OBJECTIVES: To evaluate the patient-reported burden of atherosclerotic cardiovascular disease (ASCVD) risk, this study compared patient reported outcomes (PROs) and direct costs among high-risk and non-high-risk adults with dyslipidemia in Japan.
METHODS: Data from the 2018-2023 Japan National Health and Wellness Survey (NHWS) among adults (≥18 years) residing in Japan with self-reported physician diagnosis of dyslipidemia were used. Guided by the 2022 Japan Atherosclerosis Society Guidelines for Prevention of ASCVD, respondents were classified as high-risk versus non-high-risk groups within primary and secondary prevention cohorts. PROs included health-related quality of life (HRQoL; EQ-5D-5L and EQ VAS), activity impairment (WPAI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Assessment (GAD-7). Direct medical costs were estimated from healthcare utilization.
RESULTS: Among 6,122 respondents (primary prevention: n=5,449; secondary prevention: n=673), 39.6% (n=2,158) were high-risk in primary prevention and 71.0% (n=478) in secondary prevention. Among both primary and secondary prevention cohorts, 63.2% of patients were treated with standard of care (i.e., Statin and/or Ezetimibe). In the primary prevention cohort, high-risk individuals reported significantly worse HRQoL compared with non-high-risk individuals (EQ-5D-5L: 0.81 vs 0.84, EQ VAS: 70.7 vs 74.9; both p<0.0001) and greater activity impairment (23.6 vs 21.0; p=0.0002), with no differences in PHQ-9 or GAD-7. In the secondary prevention cohort, PROs did not differ significantly between risk groups. Annual direct costs were higher in high-risk vs non-high-risk groups in primary (¥610,616 vs ¥449,356; p<0.0001) and secondary prevention (¥1,062,342 vs ¥696,641; p=0.0135).
CONCLUSIONS: Among adults with dyslipidemia in Japan, higher ASCVD risk was associated with worse HRQoL and higher direct costs in the primary prevention cohort. These findings suggest that, despite the majority of patients receiving standard of care, high-risk patients in the primary prevention cohort continue to experience residual humanistic and economic burden.
METHODS: Data from the 2018-2023 Japan National Health and Wellness Survey (NHWS) among adults (≥18 years) residing in Japan with self-reported physician diagnosis of dyslipidemia were used. Guided by the 2022 Japan Atherosclerosis Society Guidelines for Prevention of ASCVD, respondents were classified as high-risk versus non-high-risk groups within primary and secondary prevention cohorts. PROs included health-related quality of life (HRQoL; EQ-5D-5L and EQ VAS), activity impairment (WPAI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Assessment (GAD-7). Direct medical costs were estimated from healthcare utilization.
RESULTS: Among 6,122 respondents (primary prevention: n=5,449; secondary prevention: n=673), 39.6% (n=2,158) were high-risk in primary prevention and 71.0% (n=478) in secondary prevention. Among both primary and secondary prevention cohorts, 63.2% of patients were treated with standard of care (i.e., Statin and/or Ezetimibe). In the primary prevention cohort, high-risk individuals reported significantly worse HRQoL compared with non-high-risk individuals (EQ-5D-5L: 0.81 vs 0.84, EQ VAS: 70.7 vs 74.9; both p<0.0001) and greater activity impairment (23.6 vs 21.0; p=0.0002), with no differences in PHQ-9 or GAD-7. In the secondary prevention cohort, PROs did not differ significantly between risk groups. Annual direct costs were higher in high-risk vs non-high-risk groups in primary (¥610,616 vs ¥449,356; p<0.0001) and secondary prevention (¥1,062,342 vs ¥696,641; p=0.0135).
CONCLUSIONS: Among adults with dyslipidemia in Japan, higher ASCVD risk was associated with worse HRQoL and higher direct costs in the primary prevention cohort. These findings suggest that, despite the majority of patients receiving standard of care, high-risk patients in the primary prevention cohort continue to experience residual humanistic and economic burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR2
Topic
Economic Evaluation, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)